TI
GLMD icon

Tidal Investments’s Galmed Pharmaceuticals GLMD Stock Holding History

Tidal Investments’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-137
Closed -$69K – 1030
2021
Q3 		$69K Buy
+137
New +$71.8K ﹤0.01% 874

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tidal Investments's GLMD Position: Q4 2021 in Review

Tidal Investments sold out of Galmed Pharmaceuticals (GLMD) in Q4 2021, closing a stake of 137 shares — an estimated $69K sold.

Tidal Investments first reported a position in GLMD in Q3 2021 and held it in 1 quarter. The position peaked at $69K in Q3 2021. 24 funds tracked by Wall St. Rank hold GLMD as of Q4 2021.

  • Tidal Investments reported no remaining Galmed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Tidal Investments sold 137 Galmed Pharmaceuticals shares in Q4 2021, an estimated $69K.
  • Tidal Investments first reported a position in Galmed Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Tidal Investments's Galmed Pharmaceuticals position peaked at $69K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2021.

Based on Tidal Investments's 13F filing for Q4 2021, filed 16 Feb 2022.